Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (URANUS)
NCT02969083Phase 2Recruiting
- Sponsor
- European Uro-Oncology Group
- Start
- May 2018
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, cisplatin, methotrexate, vinblastine and doxorubicin in upper tract urothelial carcinoma (UTUC) (5 arms), sponsored by European Uro-Oncology Group. Primary endpoint: Proportion of patients able to start and finalize three courses of planned chemotherapy at 6 months. Started May 2018; status: recruiting.
02
Drugs
gemcitabinecisplatinmethotrexatevinblastinedoxorubicin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT02969083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969083.